v3.26.1
Segment Information
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Information
12.
Segment Information

The Company operates and manages its business as one operating segment and one reportable segment, which is focused on developing targeted therapies to treat rare lung diseases. The CODM manages the Company’s operations on a consolidated basis, assesses performance for the operating segment and decides how to allocate resources based on consolidated operating results, which is reported on the consolidated statements of comprehensive loss.

The monitoring of budgeted versus actual results is used in assessing the performance of the operating segment and in establishing resource allocation across the organization. Depreciation expense, amortization expense, stock-based compensation expense, and non-cash lease expense are significant noncash items included in net loss and reported on the consolidated statements of cash flows. The measure of segment assets is reported on the consolidated balance sheets as total assets. Expenditures for additions to long-lived assets, which include purchases of property and equipment, are included in total assets, reviewed by the CODM, and are reported on the consolidated statements of cash flows.

The following table represents information about segment loss and significant segment expenses (in thousands):

 

 

Three Months Ended March 31,

 

 

2026

 

 

2025

 

Direct research and development expenses by program:

 

 

 

 

 

 

AP01

 

$

13,155

 

 

$

10,939

 

AP02

 

 

4,719

 

 

 

729

 

AP03

 

 

228

 

 

 

351

 

Unallocated research and development expenses:

 

 

 

 

 

 

Personnel-related (excluding stock-based compensation)

 

 

4,063

 

 

 

2,867

 

Facility and information technology allocated expenses
   and other research and development costs

 

 

320

 

 

 

270

 

General and administrative expenses:

 

 

 

 

 

 

Personnel-related (excluding stock-based compensation)

 

 

2,280

 

 

 

1,459

 

Facility expenses and information technology

 

 

293

 

 

 

147

 

General corporate expenses and professional fees

 

 

1,595

 

 

 

1,402

 

Other segment items (1)

 

 

216

 

 

 

(661

)

Net loss

 

$

26,869

 

 

$

17,503

 

 

(1)
For the three months ended March 31, 2026, other segment items consist of $0.9 million of interest income, $0.2 million accretion of marketable securities, $1.2 million of stock-based compensation expense, $0.1 million of interest expense and less than $0.1 million of depreciation expense and other expenses. For the three months ended March 31, 2025, other segment items consist of $0.7 million of interest income, $0.6 million accretion of marketable securities, $0.5 million of stock-based compensation expense, and less than $0.1 million of depreciation expense and other expenses.

Direct research and development expenses by program consist primarily of costs paid to third-parties including CROs, CMOs, consultants, advisors, and other clinical study-related vendors.

Unallocated research and development expenses consist primarily of personnel-rated expenses and allocated information technology and facility expenses and other research and development related costs, excluding non-cash items, such as stock-based compensation and depreciation.

General and administrative expenses consist primarily of personnel-rated expenses, including salaries, payroll tax, bonuses, and benefits, and professional services fees for legal, finance, human resources, in addition to information technology expenses, rent expense, and other administrative functions, excluding non-cash expenses such as stock-based compensation and depreciation.

Other segment items consist primarily of interest income on cash and cash equivalents, partially offset by non-cash expenses, such as stock-based compensation and depreciation, and amortization of discounts and premiums on marketable securities.